Fairness in cost-benefit analysis: A methodology for health techonology assessment
| Autor: | Samson, Anne-Laure, Schokkaert, Erik, Thebaut, Clémence, Dormont, Brigitte, Fleurbaey, Marc, Luchini, Stéphane, Van de Voorde, Karine |
|---|---|
| Přispěvatelé: | Laboratoire d'Economie de Dauphine (LEDa), Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Laboratoire d'Economie et de Gestion des Organisations de Santé (Legos), Center of Operation Research and Econometrics [Louvain] (CORE), Université Catholique de Louvain = Catholic University of Louvain (UCL), Observatoire des Mutations Institutionnelles et Juridiques (OMIJ), Gouvernance des Institutions et des Organisations (GIO), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Haute Autorité de Santé [Saint-Denis La Plaine] (HAS), Woodrow Wilson School of Public and International Affairs (WWSPIL), Princeton University, Aix-Marseille Sciences Economiques (AMSE), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Department of Economics, KU Leuven |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
JEL: I - Health
Education and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets distributional weights JEL: I - Health Education and Welfare/I.I3 - Welfare Well-Being and Poverty/I.I3.I31 - General Welfare Well-Being [QFIN]Quantitative Finance [q-fin] JEL: D - Microeconomics/D.D6 - Welfare Economics/D.D6.D61 - Allocative Efficiency • Cost–Benefit Analysis Antihypertensive treatment cost-benefit analysis equivalent income JEL: H - Public Economics/H.H5 - National Government Expenditures and Related Policies/H.H5.H53 - Government Expenditures and Welfare Programs JEL: I - Health Education and Welfare/I.I1 - Health/I.I1.I12 - Health Behavior |
| Zdroj: | Health Economics Health Economics, 2018, 27 (1), pp.102-114. ⟨10.1002/hec.3515⟩ |
| Popis: | International audience; We evaluate the introduction of various forms of antihypertensive treatments in France with a distribution-sensitive cost-benefit analysis. Compared to traditional cost-benefit analysis, we implement distributional weighting based on equivalent incomes, a new concept of individual well-being that does respect individual preferences but is not subjectively welfarist. Individual preferences are estimated on the basis of a contingent valuation question, introduced into a representative survey of the French population. Compared to traditional cost-effectiveness analysis in health technology assessment, we show that it is feasible to go beyond a narrow evaluation of health outcomes while still fully exploiting the sophistication of medical information. Sensitivity analysis illustrates the relevancy of this richer welfare framework, the importance of the distinction between an ex ante and an ex post approach, and the need to consider distributional effects in a broader institutional setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|